Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WPV01 in mild/moderate COVID-19
NCT05752175Phase 2Completed
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing WPV01 with Placebo (2 arms). Primary endpoint: Changes in viral load at Day 7. Started Mar 2023; status: completed.
02
Drugs
iscartrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05752175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05752175.